2-chloro-1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone | 404010-44-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-chloro-1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone
• 英文别名: 2-Chloro-1-(2-hydroxy4-morpholin-4-yl phenyl)-ethanone；2-chloro-1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone
• CAS: 404010-44-2
• 化学式: C₁₂H₁₄ClNO₃
• 分子量: 255.701
• InChiKey: OBFDHTCONYPRON-UHFFFAOYSA-N

物化性质

• 沸点：
  464.1±45.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  吗啉 、 2-chloro-1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone 在 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 1-(2-hydroxy-4-morpholin-4-yl-phenyl)-2-morpholin-4-yl-ethanone
  参考文献：
  名称：

  Materials and methods to potentiate cancer treatment

  摘要：

  抑制DNA依赖性蛋白激酶的化合物，包含这些化合物的组合物，抑制DNA-PK生物活性的方法，使细胞对引起DNA损伤的药物敏感的方法，以及增强癌症治疗的方法被披露。

  公开号：

  US20020165218A1
• 作为产物：
  描述：

  3-(4-吗啉基)苯酚 、 氯乙腈 在 三氯化铝 、 三氯化硼 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以10.9%的产率得到2-chloro-1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone
  参考文献：
  名称：

  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold

  摘要：

  Phosphoinositide 3-kinases (PI3-Ks) are an ubiquitous class of signaling enzymes that regulate diverse cellular processes including growth, differentiation, and motility. Physiological roles of PI3-Ks have traditionally been assigned using two pharmacological inhibitors, LY294002 and wortmannin. Although these compounds are broadly specific for the PI3-K family, they show little selectivity among family members, and the development of isoform-specific inhibitors of these enzymes has been long anticipated. Herein, we prepare compounds from two classes of arylmorpholine PI3-K inhibitors and characterize their specificity against a comprehensive panel of targets within the PI3-K family. We identify multiplex inhibitors that potently inhibit distinct subsets of PI3-K isoforms, including the first selective inhibitor of p110beta/p110delta (IC50 p110beta = 0.13 muM, p110delta = 0.63 muM). We also identify trends that suggest certain PI3-K isoforms may be more sensitive to potent inhibition by arylmorpholines, thereby guiding future drug design based on this pharmacophore. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.06.022

文献信息

• Methods of inhibiting leukocyte accumulation
  申请人：Diacovo G. Thomas

  公开号：US20050054614A1

  公开（公告）日：2005-03-10

  The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting leukocyte accumulation comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) activity in endothelial cells.

  本发明总体上涉及磷酸肌醇 3-激酶（PI3K），更具体地说，涉及通过选择性地抑制内皮细胞中磷酸肌醇 3-激酶δ（PI3Kδ）的活性来抑制白细胞聚集的方法。
• Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
  申请人：Bouscary Didier

  公开号：US20060106038A1

  公开（公告）日：2006-05-18

  The invention relates generally to methods for treating and/or preventing aberrant proliferation of hematopoietic cells. More particularly, the invention relates to methods for treating and/or preventing aberrant proliferation of hematopoietic cells comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) activity in hematopoietic cells. The methods may be used to treat any indication involving aberrant proliferation of hematopoietic cells.

  本发明一般涉及治疗和/或预防造血细胞异常增殖的方法。更具体地说，本发明涉及治疗和/或预防造血细胞异常增殖的方法，包括选择性地抑制造血细胞中磷酸肌醇 3-激酶δ（PI3Kδ）的活性。这些方法可用于治疗任何涉及造血细胞异常增殖的病症。
• MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT
  申请人：ICOS CORPORATION

  公开号：EP1351946A2

  公开（公告）日：2003-10-15
• PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION
  申请人：ICOS CORPORATION

  公开号：EP1885356A2

  公开（公告）日：2008-02-13
• Methods of inhibiting immune responses stimulated by an endogenous factor
  申请人：Douangpanya Jason

  公开号：US20050043239A1

  公开（公告）日：2005-02-24

  The present invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting undesirable immune responses without inhibiting desired immune responses. In one embodiment, the invention provides methods of inhibiting an endogenous immune response stimulated by at least one endogenous factor without substantially inhibiting an exogenous immune response stimulated by at least one exogenous factor comprising administering an amount of a phosphoinositide 3-kinase delta (PI3Kδ) selective inhibitor effective to inhibit the endogenous immune response stimulated by endogenous factor without substantially inhibiting the exogenous immune response stimulated by the at least one exogenous factor.